Literature DB >> 28159159

Respiratory Syncytial Virus Infection: An Illness for All Ages.

Edward E Walsh1.   

Abstract

Respiratory syncytial virus (RSV) is the single most important cause of severe respiratory infection in very young infants. It has also been recently recognized as a significant cause of severe illness in elderly adults, those with underlying cardiopulmonary disease, and the immunocompromised. RSV is suspected of playing a major role in the development of asthma. Prophylaxis in high-risk infants using a monoclonal antibody is the only effective specific therapy available but recent breakthroughs in vaccine design and antiviral drugs offer the promise of effective prophylactic and therapeutic agents against RSV.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adults; Antivirals; Asthma; Bronchiolitis; Chronic obstructive pulmonary disease; Respiratory syncytial virus; Vaccines

Mesh:

Substances:

Year:  2016        PMID: 28159159      PMCID: PMC5844562          DOI: 10.1016/j.ccm.2016.11.010

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  58 in total

1.  Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children.

Authors:  Chadi M El Saleeby; Andy J Bush; Lisa M Harrison; Jody A Aitken; John P Devincenzo
Journal:  J Infect Dis       Date:  2011-10-01       Impact factor: 5.226

Review 2.  Early-Life Origins of Chronic Obstructive Pulmonary Disease.

Authors:  Fernando D Martinez
Journal:  N Engl J Med       Date:  2016-09-01       Impact factor: 91.245

3.  Concurrent serious bacterial infections in 2396 infants and children hospitalized with respiratory syncytial virus lower respiratory tract infections.

Authors:  Kevin Purcell; Jaime Fergie
Journal:  Arch Pediatr Adolesc Med       Date:  2002-04

4.  Viral shedding and immune responses to respiratory syncytial virus infection in older adults.

Authors:  Edward E Walsh; Derick R Peterson; Aja E Kalkanoglu; Frances Eun-Hyung Lee; Ann R Falsey
Journal:  J Infect Dis       Date:  2013-02-04       Impact factor: 5.226

5.  Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals.

Authors:  Ann R Falsey; Edward E Walsh; Jose Capellan; Stefan Gravenstein; Maria Zambon; Eddy Yau; Geoffrey J Gorse; Robert Edelman; Frederick G Hayden; Janet E McElhaney; Kathleen M Neuzil; Kristen L Nichol; Eric A F Simões; Peter F Wright; Valérie M-P Sales
Journal:  J Infect Dis       Date:  2008-11-01       Impact factor: 5.226

6.  Consequences of immature and senescent immune responses for infection with respiratory syncytial virus.

Authors:  Allison M W Malloy; Ann R Falsey; Tracy J Ruckwardt
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

7.  High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections.

Authors:  N Lee; G C Y Lui; K T Wong; T C M Li; E C M Tse; J Y C Chan; J Yu; S S M Wong; K W Choi; R Y K Wong; K L K Ngai; D S C Hui; P K S Chan
Journal:  Clin Infect Dis       Date:  2013-07-21       Impact factor: 9.079

8.  High Viral Load and Respiratory Failure in Adults Hospitalized for Respiratory Syncytial Virus Infections.

Authors:  Nelson Lee; Martin C W Chan; Grace C Y Lui; Ran Li; Rity Y K Wong; Irene M H Yung; Catherine S K Cheung; Eugenia C Y Chan; David S C Hui; Paul K S Chan
Journal:  J Infect Dis       Date:  2015-04-22       Impact factor: 5.226

9.  Respiratory syncytial virus- and human metapneumovirus-associated emergency department and hospital burden in adults.

Authors:  Kyle Widmer; Marie R Griffin; Yuwei Zhu; John V Williams; H Keipp Talbot
Journal:  Influenza Other Respir Viruses       Date:  2014-02-07       Impact factor: 4.380

10.  Estimates of mortality attributable to influenza and RSV in the United States during 1997-2009 by influenza type or subtype, age, cause of death, and risk status.

Authors:  Gonçalo Matias; Robert Taylor; François Haguinet; Cynthia Schuck-Paim; Roger Lustig; Vivek Shinde
Journal:  Influenza Other Respir Viruses       Date:  2014-06-27       Impact factor: 4.380

View more
  24 in total

1.  Vaccine Prevention of Respiratory Syncytial Virus Infection in Older Adults: The Work Continues.

Authors:  Joanne M Langley
Journal:  J Infect Dis       Date:  2017-12-12       Impact factor: 5.226

Review 2.  The role of vaccines in preventing bacterial antimicrobial resistance.

Authors:  Kathrin U Jansen; Charles Knirsch; Annaliesa S Anderson
Journal:  Nat Med       Date:  2018-01-09       Impact factor: 53.440

3.  Maternal RSV vaccine development. Where to from here?

Authors:  Ahinsa Gunatilaka; Michelle L Giles
Journal:  Hum Vaccin Immunother       Date:  2021-09-09       Impact factor: 4.526

4.  Targeting Host Cell Surface Nucleolin for RSV Therapy: Challenges and Opportunities.

Authors:  Peter Mastrangelo; Michael J Norris; Wenming Duan; Edward G Barrett; Theo J Moraes; Richard G Hegele
Journal:  Vaccines (Basel)       Date:  2017-09-19

Review 5.  Melittin: a venom-derived peptide with promising anti-viral properties.

Authors:  Hamed Memariani; Mojtaba Memariani; Hamideh Moravvej; Mohammad Shahidi-Dadras
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-17       Impact factor: 3.267

6.  Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium.

Authors:  Carmen Mirabelli; Martine Jaspers; Mieke Boon; Mark Jorissen; Mohamed Koukni; Dorothée Bardiot; Patrick Chaltin; Arnaud Marchand; Johan Neyts; Dirk Jochmans
Journal:  J Antimicrob Chemother       Date:  2018-07-01       Impact factor: 5.790

Review 7.  Contribution of Cytokines to Tissue Damage During Human Respiratory Syncytial Virus Infection.

Authors:  Karen Bohmwald; Nicolás M S Gálvez; Gisela Canedo-Marroquín; Magdalena S Pizarro-Ortega; Catalina Andrade-Parra; Felipe Gómez-Santander; Alexis M Kalergis
Journal:  Front Immunol       Date:  2019-03-18       Impact factor: 7.561

Review 8.  Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing.

Authors:  Kevin J Whaley; Larry Zeitlin
Journal:  Hum Vaccin Immunother       Date:  2021-07-14       Impact factor: 4.526

9.  Expanding severe acute respiratory infection (SARI) surveillance beyond influenza: The process and data from 1 year of implementation in Vietnam.

Authors:  Karen A Alroy; Trang Thuy Do; Phu Dac Tran; Tan Quang Dang; Long Ngoc Vu; Nga Thi Hang Le; Anh Duc Dang; Nghia Duy Ngu; Tu Huy Ngo; Phuong Vu Mai Hoang; Lan Trong Phan; Thuong Vu Nguyen; Long Thanh Nguyen; Thinh Viet Nguyen; Mai Quang Vien; Huy Xuan Le; Anh The Dao; Trieu Bao Nguyen; Duoc Tho Pham; Van Thi Tuyet Nguyen; Thanh Ngoc Pham; Binh Hai Phan; Brett Whitaker; Thuy Thi Thu Do; Phuong Anh Dao; S Arunmozhi Balajee; Anthony W Mounts
Journal:  Influenza Other Respir Viruses       Date:  2018-06-10       Impact factor: 4.380

10.  Characterization of circulating RSV strains among subjects in the OUTSMART-RSV surveillance program during the 2016-17 winter viral season in the United States.

Authors:  Alexey Ruzin; Susan T Pastula; Elizabeth Levin-Sparenberg; Xiaohui Jiang; Jon Fryzek; Andrey Tovchigrechko; Bin Lu; Yanping Qi; Hui Liu; Hong Jin; Li Yu; Judith Hackett; Tonya Villafana; Mark T Esser
Journal:  PLoS One       Date:  2018-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.